메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)

Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing BROADMEADOWS, AUSTRALIA, Oct. 27, 2025 -- CSL's base fractionation facility in Broadmeadows, Australia has been recognised as the Overall Winner of the 2025 Facility of the Year Award (FOYA) by the International Society for Pharmaceutical Engineering (ISPE). Purpose-built to optimise the production of plasma-derived therapies for conditions such as immunodeficiencies, neurological disorders, and burns
- 황정호 기자
- 2025-10-27 11:23
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer

SUZHOU, China, Oct. 27, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to initiate a Phase III clinical study (Study ID: JSKN003-005) for the treatment of HER2-positive advanced colorectal cancer (CRC). This marks
- 김갑성 기자
- 2025-10-27 09:51
Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025

SHANGHAI and HONG KONG, Oct. 27, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the latest preclinical data of ATG-201 (CD19 x CD3 TCE) were presented in a Poster Presentation at the 2025 American College of Rheumatology (ACR) Annual Meeting, taking place from October 24th to October 29th in
- 김갑성 기자
- 2025-10-27 09:00
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3

[ 메디채널 김갑성 기자 ] The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head comparison with semaglutide in diabetes treatment SAN FRANCISCO and SUZHOU, China, Oct. 27, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for th
- 김갑성 기자
- 2025-10-27 08:00
Real-World Data Presented at TCT 2025 Demonstrates the EggNest™ Complete Radiation Protection System Significantly Reduces Radiation Exposure for the Entire Cath Lab Team

SAN FRANCISCO, Oct. 26, 2025 -- At the 2025 Transcatheter Cardiovascular Therapeutics® (TCT) Conference, Dr. Jarrod Frizzell of The Christ Hospital (Cincinnati, OH) presented real-world studies¹,² demonstrating that the EggNest™ Complete Radiation Protection System from Egg Medical, Inc. (Roseville, MN) dramatically reduces radiation exposure for all members of the interventional team — including physicians, nurses, and technologists — compared to traditional shielding methods. During X-ray–guided cardiovascular procedures, scatter radiation poses a well-documented occup
- 김갑성 기자
- 2025-10-27 01:00
WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance

Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY; Revenue from Continuing Operations[1] Reached RMB12.04 Billion, Up 19.7% YoY Q1-Q3 Total Revenue: RMB32.86 Billion, Up 18.6% YoY; Revenue from Continuing Operations Reached RMB32.45 Billion, Up 22.5% YoY Q1-Q3 Net Profit Attributable to Owners of the Company Reached RMB12.08 Billion[2], Up 84.8% YoY; Diluted Earnings per Share (EPS) of RMB4.21[3], Up 87.9% YoY Q1-Q3 Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company Reached RMB10.54 Billion, Up 43.4% YoY;
- 김갑성 기자
- 2025-10-26 15:53
Indonesia's Legacy in the Global Vaccine Landscape, Bio Farma and DCVMN Strengthen Health Resilience Through Global Partnership

BANDUNG, Indonesia, Oct. 25, 2025 -- Through PT Bio Farma (Persero), Indonesia has played a strategic and sustained role in the Developing Countries Vaccine Manufacturers' Network (DCVMN), working to ensure equitable access to safe, high-quality, and affordable vaccines. Since DCVMN's founding in 2000, Bio Farma has been a key driver in advancing vaccine self-reliance and public health capacity in developing countries. Collaboration between Bio Farma and DCVMN has been established since the inception of the network. At the first DCVMN Annual General Meeting in Noordwijk in 2000
- 김갑성 기자
- 2025-10-25 18:52
MHTC WELCOMES ROYAL OMAN POLICE TO ENHANCE GOVERNMENT-TO-GOVERNMENT COOPERATION

KUALA LUMPUR, Malaysia, Oct. 25, 2025 -- Malaysia Healthcare Travel Council (MHTC) concluded a four-day familiarisation visit by senior Royal Oman Police (ROP) officials from 21 to 24 October 2025. The delegation, led by Brigadier Dr Naseer Al-Manthery, Director General of Medical Services for Security Services, visited leading Malaysian hospitals and patient facilitation centres to evaluate clinical capabilities and care coordination systems. The visit builds on government-to-government engagement between MHTC and ROP that began in January 2025, when both organisations first d
- 김갑성 기자
- 2025-10-25 17:04
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement

[ 메디채널 김갑성 기자 ] The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the "Company") today announced the successful completion of patient enrollment in the Cardiovalve TARGET study for Transcatheter Tricuspid Valve Replacement (TTVR), with a total of 150 patients enrolled. The completion of enrollment marks a major milestone toward European regulatory approval for Cardiovalve's Transcatheter Tricuspid Valve Re
- 김갑성 기자
- 2025-10-25 15:00
Breathe Easy This Fall: VARON Supports Respiratory Wellness During Seasonal Change

NEW YORK, Oct. 25, 2025 -- As cooler temperatures and shifting air quality arrive, many families notice changes in their breathing. Dry air, allergens, and sudden cold snaps can worsen conditions like asthma or COPD, making respiratory health a top priority during the season. To help address these seasonal challenges, VARON, a leading provider of affordable oxygen solutions, is reinforcing its commitment to respiratory wellness with both education and dependable oxygen therapy products. Through its innovative line of affordable oxygen solutions—including the Seren
- 김갑성 기자
- 2025-10-25 08:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-11-03_MON

2025-11-02_SUN

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 03일 07시 00분